Compare OSRH & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSRH | BFRI |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 22 | 94 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 16.3M |
| IPO Year | N/A | N/A |
| Metric | OSRH | BFRI |
|---|---|---|
| Price | $0.44 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | ★ 626.7K | 338.4K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.57 |
| 52 Week High | $1.24 | $1.27 |
| Indicator | OSRH | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 65.52 |
| Support Level | $0.40 | $0.73 |
| Resistance Level | $0.45 | N/A |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 28.95 | 92.73 |
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.